Home HCP pJIA

 

Xatmep: The first and only FDA-approved methotrexate oral solution for the management of POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (pJIA) in pediatric patients.


  • Assured efficacy delivered with consistent potency.1
  • The first and only FDA-approved methotrexate oral solution for pJIA.
  • Oral solution provides consistent stability when stored as directed.2
  • No compounding or crushing tablets necessary.
  • No methotrexate injections necessary.
  • Body surface area-based dosing.

Stay Up To Date

Get the latest updates on Xatmep

First Name *

Last Name *

Practice
Setting

Professional
Designation

Practice
Specialty

Email Address*

Phone*

City

State

ZIP Code *

*Required Information
By clicking Submit, you allow Silvergate Pharmaceuticals, Inc. to give you information on Xatmep and other Silvergate products. Please see privacy policy here.